# A Study Of The Selective PKC-β Inhibitor MS- 553

> **NCT03492125** · PHASE1,PHASE2 · TERMINATED · sponsor: **MingSight Pharmaceuticals, Inc** · enrollment: 60 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia
- Small Lymphocytic Lymphoma
- Aggressive Lymphoma

## Interventions

- **DRUG:** MS-553
- **DRUG:** MS-553
- **DRUG:** acalabrutinib
- **DRUG:** venetoclax
- **DRUG:** Rituximab
- **DRUG:** obinutuzumab

## Key facts

- **NCT ID:** NCT03492125
- **Lead sponsor:** MingSight Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-25
- **Primary completion:** 2023-11-28
- **Final completion:** 2023-11-28
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** The study is terminated due to major protocol revisions. A new study in CLL patients is planned.
- **Last updated:** 2025-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03492125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03492125, "A Study Of The Selective PKC-β Inhibitor MS- 553". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03492125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*